TY - JOUR
T1 - International collaborative study to assess cardiovascular risk and evaluate long-term health in cats with preclinical hypertrophic cardiomyopathy and apparently healthy cats: The REVEAL Study
AU - Fox, Philip R.
AU - Keene, Bruce W.
AU - Lamb, Kenneth
AU - Schober, Karsten A.
AU - Chetboul, Valerie
AU - Fuentes, Virginia Luis
AU - Wess, Gerhard
AU - Payne, Jessie Rose
AU - Hogan, Daniel F.
AU - Motsinger-Reif, Alison
AU - Haggstrom, Jens
AU - Trehiou-Sechi, Emilie
AU - Fine-Ferreira, Deborah M.
AU - Nakamura, Reid K.
AU - Lee, Pamela M.
AU - Singh, Manreet K.
AU - Ware, Wendy A.
AU - Abbott, Jonathan A.
AU - Culshaw, Geoffrey
AU - Riesen, Sabine
AU - Borgarelli, Michele
AU - Lesser, Michael B.
AU - Van Israel, Nicole
AU - Cote, Etienne
AU - Rush, John E.
AU - Bulmer, Barret
AU - Santilli, Roberto A.
AU - Vollmar, Andrea C.
AU - Bossbaly, Maribeth J.
AU - Quick, Nadine
AU - Bussadori, Claudio
AU - Bright, Janice M.
AU - Estrada, Amara H.
AU - Ohad, Dan G.
AU - Fernandez-Del Palacio, Maria Josefa
AU - Brayley, Jenifer Lunney
AU - Schwartz, Denise S.
AU - Bove, Christina M.
AU - Gordon, Sonya G.
AU - Jung, Seung Woo
AU - Brambilla, Paola
AU - Moise, N. Sydney
AU - Stauthammer, Christopher D.
AU - Stepien, Rebecca L.
AU - Quintavalla, Cecilia
AU - Amberger, Christophe
AU - Manczur, Ferenc
AU - Hung, Yong-Wei
AU - Lobetti, Remo
AU - De Swarte, Marie
AU - Tamborini, Alice
AU - Mooney, Carmel T.
AU - Oyama, Mark A.
AU - Komolov, Andrey
AU - Fujii, Yoko
AU - Pariaut, Romain
AU - Uechi, Masami
AU - Ohara, Victoria Yukie Tachika
PY - 2018
Y1 - 2018
N2 - BackgroundHypertrophic cardiomyopathy is the most prevalent heart disorder in cats and principal cause of cardiovascular morbidity and mortality. Yet, the impact of preclinical disease is unresolved.Hypothesis/ObjectivesObservational study to characterize cardiovascular morbidity and survival in cats with preclinical nonobstructive (HCM) and obstructive (HOCM) hypertrophic cardiomyopathy and in apparently healthy cats (AH).AnimalsOne thousand seven hundred and thirty client-owned cats (430 preclinical HCM; 578 preclinical HOCM; 722 AH).MethodsRetrospective multicenter, longitudinal, cohort study. Cats from 21 countries were followed through medical record review and owner or referring veterinarian interviews. Data were analyzed to compare long-term outcomes, incidence, and risk for congestive heart failure (CHF), arterial thromboembolism (ATE), and cardiovascular death.ResultsDuring the study period, CHF, ATE, or both occurred in 30.5% and cardiovascular death in 27.9% of 1008 HCM/HOCM cats. Risk assessed at 1, 5, and 10 years after study entry was 7.0%/3.5%, 19.9%/9.7%, and 23.9%/11.3% for CHF/ATE, and 6.7%, 22.8%, and 28.3% for cardiovascular death, respectively. There were no statistically significant differences between HOCM compared with HCM for cardiovascular morbidity or mortality, time from diagnosis to development of morbidity, or cardiovascular survival. Cats that developed cardiovascular morbidity had short survival (meanstandard deviation, 1.3 +/- 1.7 years). Overall, prolonged longevity was recorded in a minority of preclinical HCM/HOCM cats with 10% reaching 9-15 years.Conclusions and Clinical ImportancePreclinical HCM/HOCM is a global health problem of cats that carries substantial risk for CHF, ATE, and cardiovascular death. This finding underscores the need to identify therapies and monitoring strategies that decrease morbidity and mortality.
AB - BackgroundHypertrophic cardiomyopathy is the most prevalent heart disorder in cats and principal cause of cardiovascular morbidity and mortality. Yet, the impact of preclinical disease is unresolved.Hypothesis/ObjectivesObservational study to characterize cardiovascular morbidity and survival in cats with preclinical nonobstructive (HCM) and obstructive (HOCM) hypertrophic cardiomyopathy and in apparently healthy cats (AH).AnimalsOne thousand seven hundred and thirty client-owned cats (430 preclinical HCM; 578 preclinical HOCM; 722 AH).MethodsRetrospective multicenter, longitudinal, cohort study. Cats from 21 countries were followed through medical record review and owner or referring veterinarian interviews. Data were analyzed to compare long-term outcomes, incidence, and risk for congestive heart failure (CHF), arterial thromboembolism (ATE), and cardiovascular death.ResultsDuring the study period, CHF, ATE, or both occurred in 30.5% and cardiovascular death in 27.9% of 1008 HCM/HOCM cats. Risk assessed at 1, 5, and 10 years after study entry was 7.0%/3.5%, 19.9%/9.7%, and 23.9%/11.3% for CHF/ATE, and 6.7%, 22.8%, and 28.3% for cardiovascular death, respectively. There were no statistically significant differences between HOCM compared with HCM for cardiovascular morbidity or mortality, time from diagnosis to development of morbidity, or cardiovascular survival. Cats that developed cardiovascular morbidity had short survival (meanstandard deviation, 1.3 +/- 1.7 years). Overall, prolonged longevity was recorded in a minority of preclinical HCM/HOCM cats with 10% reaching 9-15 years.Conclusions and Clinical ImportancePreclinical HCM/HOCM is a global health problem of cats that carries substantial risk for CHF, ATE, and cardiovascular death. This finding underscores the need to identify therapies and monitoring strategies that decrease morbidity and mortality.
KW - arterial thromboembolism
KW - asymptomatic
KW - congestive heart failure
KW - epidemiology
KW - incidence
KW - outcome
KW - survival
KW - arterial thromboembolism
KW - asymptomatic
KW - congestive heart failure
KW - epidemiology
KW - incidence
KW - outcome
KW - survival
UR - https://res.slu.se/id/publ/95807
U2 - 10.1111/jvim.15122
DO - 10.1111/jvim.15122
M3 - Journal article
C2 - 29660848
SN - 0891-6640
VL - 32
SP - 930
EP - 943
JO - Journal of Veterinary Internal Medicine
JF - Journal of Veterinary Internal Medicine
IS - 3
ER -